---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-028676"
form_type: "8-K/A"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:07:43.258924+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Hookipa restates Gilead deal, gets $35M equity; HIV R&D expanded

## Summary
- Hookipa assumes additional HIV development responsibility under restated collaboration agreement.
- Gilead to purchase up to $35 million of Hookipa common stock to support increased HIV R&D.
- Restated agreement covers HBV and HIV vaccine programs using Hookipa's arenavirus technology.
- Financial milestones and royalties are redacted but original 2018 deal amended.
- Full collaboration agreement filed as Exhibit 10.1 to Form 8-K/A.

## SEC filing metadata
- accession: 0001104659-22-028676
- form_type: 8-K/A
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/0001104659-22-028676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/tm227839d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-028676
- JSON: https://secwatch.observer/filing/0001104659-22-028676.json
- Plain text: https://secwatch.observer/filing/0001104659-22-028676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.